Gut Kidney Axis in Enteric Hyperoxaluria

Enteric Hyperoxaluria Clinical Trial

Official title:

Gut Kidney Axis in Enteric Hyperoxaluria: A Clinical Prospective Study of the Effects of the Microbiome on Urinary Oxalate in Participants With Enteric Hyperoxaluria Fed a Moderate Oxalate Diet

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05124886
• Other study ID #: 21-01274
• Secondary ID: R01DK128842
• Status: Recruiting
• Phase: N/A
• Start date: November 10, 2022
• Est. completion date: May 1, 2026

Study information

• Verified date: March 2024
• Source: NYU Langone Health
• Contact: Lama Nazzal, MD
• Phone: 212-263-2922
• Email: Lama.Nazzal[@]nyulangone.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

40 subjects with a confirmed diagnosis of IBD or >6 months post-RYGB with a diagnosed USD event or kidney stone on imaging within the past three years and 40 healthy controls will be administered a high oxalate diet on Days 0-3 and Days 21-24 with a washout period on Days 4-7 and will be administered 250mg sodium oxalate on Days 8-20, via prepared spinach, from Weil Cornell Medicine's Clinical and Translational Science Center. Subjects will partake in four stool collections, four 24-h urine collections, two blood collections, and four sets of colonic permeability testing.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: May 1, 2026
• Est. primary completion date: June 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the

following criteria:

• Subjects > 18 years and < 80 years of age
• a confirmed diagnosis of IBD or > 6 months post- RYGB, with a diagnosis USD event (renal colic with spontaneous stone passage, emergency room visits, or urological interventions) or have kidney stone on imaging (CT, MRI, or US) in the previous three years.
• We will include all racial and ethnic groups, and both men and women. In order to be eligible in this study as a healthy control, an individual must meet all of

the following criteria:

• Subjects > 18 years and < 80 years of age
• Healthy controls with no chronic diseases, not on any chronic medications, no history of GI pathology, or urinary stone disease (USD).
• We will include all racial and ethnic groups, and both men and women. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation

in this study:

• pregnant or nursing women and people with any medical, psychiatric, debilitating disease/disorder or social condition that, in the judgment of the investigator, would interfere with or serve as a contraindication to adherence to the study protocol, ability to give ICF or complete the protocol.
• subjects with total and partial colectomy.
• subjects who received oral, intramuscular, or intravenous antibiotics within three months before screening.
• Patients with perianal disease usually receive recurrent antibiotics and, therefore, will be excluded from the study.
• patients with an ongoing symptomatic IBD flare or a flare within the previous three months
• patients with estimated glomerular filtration rates (eGFR) < 60 ml/min/1.73 m2 calculated by the CKD-EPI equation measured anytime within the preceding year. An individual who meets any of the following criteria will be excluded from participation

in this study as a healthy control:

• pregnant or nursing women and people with any medical, psychiatric, debilitating disease/disorder or social condition that, in the judgment of the investigator, would interfere with or serve as a contraindication to adherence to the study protocol, ability to give ICF or complete the protocol.
• subjects with total and partial colectomy.
• subjects who received oral, intramuscular, or intravenous antibiotics within three months before screening.
• Patients with perianal disease usually receive recurrent antibiotics and, therefore, will be excluded from the study.
• patients with an ongoing symptomatic IBD flare or a flare within the previous three months
• patients with estimated glomerular filtration rates (eGFR) < 60 ml/min/1.73 m2 calculated by the CKD-EPI equation measured anytime within the preceding year.

Related Conditions & MeSH terms

• Enteric Hyperoxaluria

Intervention

Other:
• Moderately High Oxalate (MOx) Diet
Diets will contain 16% protein, 30% fat, and 54% carbohydrate, and are controlled in the amounts of calcium (400mg), oxalate (250mg), ascorbic acid (50mg), fiber (30 grams) and, other nutrients. Each controlled diet will be consumed for four days. On days of controlled diets, subjects will be provided with 2 liters of bottled water per day to ensure adequate hydration. After the controlled diet period, there will be a three-day washout period, where participants will consume Ad-lib diets supplemented with a daily intake of oxalate in the form of cooked spinach to be taken with breakfast daily for a total of 2 weeks.

Locations

Country	Name	City	State
United States	NYU Langone Health	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
NYU Langone Health	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Urinary Oxalate Levels (UOx)	UOx will be quantified in 24-h samples	Day 2-3
Primary	Urinary Oxalate Levels (UOx)	UOx will be quantified in 24-h samples	Day 23-24
Secondary	Total Fecal Oxalate Levels		Day 2-3
Secondary	Total Fecal Oxalate Levels		Day 14
Secondary	Total Fecal Oxalate Levels		Day 23-24
Secondary	Urinary Calcium Levels		Day 2-3
Secondary	Urinary Calcium Levels		Day 23-24
Secondary	Sucralose Levels		Day 2-3
Secondary	Sucralose Levels		Day 23-24
Secondary	Calcium Oxalate (CaOx) Supersaturation Levels		Day 2-3
Secondary	Calcium Oxalate (CaOx) Supersaturation Levels		Day 23-24
Secondary	Plasma Oxalate Levels		Day 2-3
Secondary	Plasma Oxalate Levels		Day 23-24